Literature DB >> 25245777

The role of the OncPal deprescribing guideline in end-of-life care.

Emily Reeve1, Danijela Gnjidic, Sarah Hilmer.   

Abstract

Mesh：

Year:  2014        PMID： 25245777     DOI： 10.1007/s00520-014-2445-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  5 in total

1.  Opportunities for deprescribing statins in patients with poor cancer prognosis.

Authors:  Justin Turner; Nimit Singhal; J Simon Bell
Journal:  J Palliat Med       Date:  2013-09-20       Impact factor: 2.947

2.  The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline'.

Authors:  Julian Lindsay; Michael Dooley; Jennifer Martin; Michael Fay; Alison Kearney; Mohsina Khatun; Michael Barras
Journal:  Support Care Cancer       Date:  2014-07-01       Impact factor: 3.603

3.  Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process.

Authors:  Emily Reeve; Sepehr Shakib; Ivanka Hendrix; Michael S Roberts; Michael D Wiese
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

Review 4.  Drug cessation in complex older adults: time for action.

Authors:  Tischa J M van der Cammen; Chakravarthi Rajkumar; Graziano Onder; Carolyn S Sterke; Mirko Petrovic
Journal:  Age Ageing       Date:  2013-11-12       Impact factor: 10.668

5.  Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study.

Authors:  Jan Schuling; Henkjan Gebben; Leonardus Johannes Gerardus Veehof; Flora Marcia Haaijer-Ruskamp
Journal:  BMC Fam Pract       Date:  2012-07-09       Impact factor: 2.497
  5 in total
  1 in total

1.  The deprescribing rainbow: a conceptual framework highlighting the importance of patient context when stopping medication in older people.

Authors:  Adam Todd; Jesse Jansen; Jim Colvin; Andrew J McLachlan
Journal:  BMC Geriatr       Date:  2018-11-29       Impact factor: 3.921
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.